Localized targeted antiangiogenic drug delivery for glioblastoma

Gregory Arnone, Abhiraj D. Bhimani, Tania Aguilar, Ankit I. Mehta

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Systemic delivery of antiangiogenic agents has been ineffective in improving the overall survival of patients with both primary and recurrent glioblastoma, in part due to dose-limiting toxicities. With the development of new and efficient localized delivery methods and vehicles, an otherwise lethal dose of antiangiogenic chemotherapy can be used to treat tumors while minimizing systemic side effects. Current in-vitro and in-vivo animal studies have shown promising results that encourage the pursuit towards human clinical trials for localized antiangiogenic treatment in the near future.

Original languageEnglish (US)
Pages (from-to)223-231
Number of pages9
JournalJournal of neuro-oncology
Volume137
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Angiogenesis Inhibitors
Glioblastoma
Clinical Trials
Drug Therapy
Survival
Pharmaceutical Preparations
Neoplasms
Therapeutics
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Arnone, Gregory ; Bhimani, Abhiraj D. ; Aguilar, Tania ; Mehta, Ankit I. / Localized targeted antiangiogenic drug delivery for glioblastoma. In: Journal of neuro-oncology. 2018 ; Vol. 137, No. 2. pp. 223-231.
@article{c22d471a259741aca0bed5110f98309d,
title = "Localized targeted antiangiogenic drug delivery for glioblastoma",
abstract = "Systemic delivery of antiangiogenic agents has been ineffective in improving the overall survival of patients with both primary and recurrent glioblastoma, in part due to dose-limiting toxicities. With the development of new and efficient localized delivery methods and vehicles, an otherwise lethal dose of antiangiogenic chemotherapy can be used to treat tumors while minimizing systemic side effects. Current in-vitro and in-vivo animal studies have shown promising results that encourage the pursuit towards human clinical trials for localized antiangiogenic treatment in the near future.",
author = "Gregory Arnone and Bhimani, {Abhiraj D.} and Tania Aguilar and Mehta, {Ankit I.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s11060-018-2747-2",
language = "English (US)",
volume = "137",
pages = "223--231",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

Localized targeted antiangiogenic drug delivery for glioblastoma. / Arnone, Gregory; Bhimani, Abhiraj D.; Aguilar, Tania; Mehta, Ankit I.

In: Journal of neuro-oncology, Vol. 137, No. 2, 01.04.2018, p. 223-231.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Localized targeted antiangiogenic drug delivery for glioblastoma

AU - Arnone, Gregory

AU - Bhimani, Abhiraj D.

AU - Aguilar, Tania

AU - Mehta, Ankit I.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Systemic delivery of antiangiogenic agents has been ineffective in improving the overall survival of patients with both primary and recurrent glioblastoma, in part due to dose-limiting toxicities. With the development of new and efficient localized delivery methods and vehicles, an otherwise lethal dose of antiangiogenic chemotherapy can be used to treat tumors while minimizing systemic side effects. Current in-vitro and in-vivo animal studies have shown promising results that encourage the pursuit towards human clinical trials for localized antiangiogenic treatment in the near future.

AB - Systemic delivery of antiangiogenic agents has been ineffective in improving the overall survival of patients with both primary and recurrent glioblastoma, in part due to dose-limiting toxicities. With the development of new and efficient localized delivery methods and vehicles, an otherwise lethal dose of antiangiogenic chemotherapy can be used to treat tumors while minimizing systemic side effects. Current in-vitro and in-vivo animal studies have shown promising results that encourage the pursuit towards human clinical trials for localized antiangiogenic treatment in the near future.

UR - http://www.scopus.com/inward/record.url?scp=85040336025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040336025&partnerID=8YFLogxK

U2 - 10.1007/s11060-018-2747-2

DO - 10.1007/s11060-018-2747-2

M3 - Review article

C2 - 29327174

AN - SCOPUS:85040336025

VL - 137

SP - 223

EP - 231

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -